Cost-effectiveness of prescreening versus empirical vaccination for hepatitis A in Egyptian children with chronic liver disease
EMHJ-Eastern Mediterranean Health Journal. 2008; 14 (4): 804-809
en Inglés
| IMEMR
| ID: emr-157217
ABSTRACT
The aim of the study was to determine the prevalence of anti-hepatitis A virus [anti-HAV] antibodies among 172 children with chronic liver disease, and to calculate the cost- effectiveness of prescreening prior to hepatitis A vaccination. Anti-HAV antibodies were positive in 85.1%. However, seroprevalence of anti-HAV antibodies was 62.1% in children < 5 years and 94.4% in children 5+ years. We conclude that while it is cost-effective to do prescreening before hepatitis A vaccination for children with chronic liver disease aged 5+ years, prescreening might not be cost-effective in those aged < 5 years
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Tamizaje Masivo
/
Enfermedad Crónica
/
Prevalencia
/
Distribución por Edad
/
Costos y Análisis de Costo
/
Anticuerpos de Hepatitis A
/
Hepatopatías
Tipo de estudio:
Evaluación Económica en Salud
/
Estudio de prevalencia
/
Estudio de tamizaje
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
East Mediterr Health J.
Año:
2008
Similares
MEDLINE
...
LILACS
LIS